ABUS three-lens brief
Evidence-based stock research on ABUS. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA above 200-day MA (golden-cross regime); price above both. · Negative free cash flow last quarterly (-$80.24M).
- 50-day MA above 200-day MA (golden-cross regime); price above both.
- Outperforming SPY by 15.5pp over 30 days.
- P/E of 6.6 — trading at a value multiple.
- Negative free cash flow last quarterly (-$80.24M).
ABUS closed at $5.12 (-0.97%) as of 2026-09-11. Market cap: $1.01B. P/E (trailing) 6.6. Price is above the 50-day MA and above the 200-day MA. Positives: 50-day MA above 200-day MA (golden-cross regime); price above both.; outperforming SPY by 15.5pp over 30 days.. Concerns: negative free cash flow last quarterly (-$80.24M).. Last quarter: Revenue $1.41M, net income -$7.16M, free cash flow -$80.24M.
Why three lenses on ABUS, not one.
A single reasoning model has blind spots it doesn’t know about. We examine ABUSacross Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/ABUS" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath ABUS brief"></iframe>